Evidence map›Paper›PMID 38822352›Full record

ArticleJournal of translational medicine2024

Neutrophils cultured ex vivo from CD34

Claire A Naveh, Kiran Roberts, Przemysław Zakrzewski, Christopher M Rice, Fernando M Ponce-Garcia, Kathryn Fleming, Megan Thompson, Nawamin Panyapiean, Huan Jiang, Stephanie Diezmann and 3 more

Erratum issuedAbstract read
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. CAR-engineered neutrophils derived from induced pluripotent stem cells: a new frontier in cellular immunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Effect of Fullerenol CNanomaterials (Basel, Switzerland) · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Claire A Naveh *School of Cellular and Molecular Medicine, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.
Kiran Roberts *School of Biochemistry, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.
Przemysław ZakrzewskiSchool of Cellular and Molecular Medicine, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.
Christopher M RiceSchool of Cellular and Molecular Medicine, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.
Fernando M Ponce-GarciaSchool of Cellular and Molecular Medicine, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.
Kathryn FlemingSchool of Cellular and Molecular Medicine, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.
Megan ThompsonSchool of Biochemistry, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.
Nawamin PanyapieanSchool of Cellular and Molecular Medicine, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.
Huan JiangSchool of Cellular and Molecular Medicine, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.
Stephanie DiezmannSchool of Cellular and Molecular Medicine, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.
Pedro L MouraCenter for Hematology and Regenerative Medicine, Department of Medicine Huddinge (MedH), Karolinska Institutet, Huddinge, Sweden.
Ashley M ToyeSchool of Biochemistry, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK. ash.m.toye@bristol.ac.uk.
Borko AmulicSchool of Cellular and Molecular Medicine, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK. borko.amulic@bristol.ac.uk.ORCID 0000-0002-8518-8393

Funding

Medical Research Council MR/R02149X/1
6 · The paper itself

Abstract

backgroundNeutrophils are granulocytes with essential antimicrobial effector functions and short lifespans. During infection or sterile inflammation, emergency granulopoiesis leads to release of immature neutrophils from the bone marrow, serving to boost circulating neutrophil counts. Steady state and emergency granulopoiesis are incompletely understood, partly due to a lack of genetically amenable models of neutrophil development.

methodsWe optimised a method for ex vivo production of human neutrophils from CD34

resultsWe obtain high yields of ex vivo cultured neutrophils, which phenotypically resemble immature neutrophils released into the circulation during emergency granulopoiesis. Cultured neutrophils have similar rates of ROS production and bacterial killing but altered degranulation, cytokine release and antifungal activity compared to mature neutrophils isolated from peripheral blood. These differences are likely due to incomplete synthesis of granule proteins, as demonstrated by proteomic analysis.

conclusionEx vivo cultured neutrophils are genetically tractable via genome editing of precursors and provide a powerful model system for investigating the properties and behaviour of immature neutrophils.

Indexed as

Antigens, CD34NeutrophilsCell DegranulationCells, CulturedCytokinesGene EditingHematopoietic Stem CellsHumansPhenotypeProteomicsReactive Oxygen SpeciesStem CellsAntigens, CD34CytokinesReactive Oxygen SpeciesCD34+stem cellsEx vivo differentiationGranulopoiesisNeutrophilProteomics

Identifiers

PMID38822352
PMCPMC11143668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.